RESUMO
ABSTRACT: Fahr syndrome is a rare neurological disorder characterized by a combination of neurological and psychiatric symptoms. Despite its complexity, there is a significant scarcity of literature addressing the treatment of the psychiatric symptoms of Fahr syndrome. This case report discusses the complexity of management of psychosis in patients with Fahr syndrome emphasizing the delicate balance required to address both psychiatric and neurological symptoms. It underscores the need for a collaborative treatment approach. Furthermore, this case report explores the potential role for electroconvulsive therapy (ECT) in management of psychosis in Fahr syndrome, a topic for which there is limited existing literature. We aim to contribute to bridging this fap with our report.
RESUMO
BACKGROUND: Postpartum depression (PPD) is a severe, debilitating mood disorder with consequences for both mothers and children, highlighting the need for rapid-acting and effective treatments for PPD. The aim of this narrative review is to synthesize the available literature on the administration of ketamine for PPD and propose ketamine as a viable and advantageous treatment. METHODS: A search was conducted on MEDLINE/PubMed, PsycInfo, and Embase databases from inception to October 10, 2021 for preclinical studies, interventional studies (ie, open-label and randomized controlled trials), as well as systematic reviews and meta-analyses evaluating the use of ketamine in postpartum populations. Completed and ongoing clinical trials were identified on ClinicalTrials.gov. RESULTS: Four clinical trials were identified. Results from this review support additional investigation into ketamine as a potential treatment for PPD. CONCLUSIONS: Ketamine may be a favorable option for treating PPD due to its antidepressive and analgesic effects, short infusion time, and rapid clearance from the maternal bloodstream. However, there is insufficient evidence to support its use in this population, underscoring the importance of additional clinical research investigating ketamine for PPD.
Assuntos
Depressão Pós-Parto , Ketamina , Feminino , Criança , Humanos , Ketamina/farmacologia , Ketamina/uso terapêutico , Depressão Pós-Parto/tratamento farmacológico , Antidepressivos/uso terapêutico , Mães , Analgésicos/farmacologia , Analgésicos/uso terapêuticoRESUMO
The impact of depression is well described in the literature, and it is most prominent in patients who have trialed multiple treatments. Treatment-resistant depression (TRD) is particularly debilitating, and it is associated with significant morbidity and mortality. Despite this, there seems to be therapeutic inertia in adopting novel therapies in current practice. Ketamine is an N-methyl-D-aspartate receptor antagonist and anesthetic agent which has recently been shown to be effective in the management of TRD when administered intravenously or intranasally. The treatments, however, are not easily accessible due to restrictions in prescribing and dispensing, high costs, and the slow uptake of evidence-based practice involving ketamine within the Canadian healthcare system. Given the limited treatment options for TRD, novel approaches should be considered and adopted into practice, and facilitated by a multi-disciplinary approach. Pharmacists play a critical role in ensuring access to quality care. This includes dissemination of evidence supporting pharmacological treatments and facilitating translation into current practice. Pharmacists are uniquely positioned to collaborate with prescribers and assess novel treatment options, such as ketamine, address modifiable barriers to treatment, and triage access to medications during transitions of care. Extending the reach of these novel psychiatric treatments in both tertiary and primary care settings creates an emerging role for pharmacists in the collaborative effort to better manage treatment-resistant depression.